Literature DB >> 23203765

Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome.

I Marie1, S Josse, P Y Hatron, S Dominique, E Hachulla, A Janvresse, P Cherin, L Mouthon, O Vittecoq, J-F Menard, F Jouen.   

Abstract

OBJECTIVE: To assess the outcome of interstitial lung disease (ILD) in anti-Jo-1 patients with antisynthetase syndrome, determine predictive variables of ILD deterioration in these patients, and compare features of anti-Jo-1 patients with and without ILD.
METHODS: Ninety-one anti-Jo-1 patients were identified by medical records search in 4 medical centers. All of these patients had undergone pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) scans.
RESULTS: Sixty-six patients (72.5%) had ILD. Patients could be divided into 3 groups according to their presenting lung manifestations: acute onset of lung disease (n = 12), progressive onset of lung signs (n = 35), and asymptomatic patients exhibiting abnormalities consistent with ILD on PFTs and HRCT scans (n = 19). Sixteen patients had resolution of ILD; 39 and 11 patients experienced improvement and deterioration of ILD, respectively. ILD led to decreased functional status, since 29.8% of patients exhibited a marked reduction of activities due to ILD and 13.6% had respiratory insufficiency requiring oxygen therapy; 5 of 6 patients died due to ILD complications. Predictive parameters of ILD deterioration were HRCT scan pattern of usual interstitial pneumonia, respiratory muscle involvement, and age ≥55 years. Furthermore, anti-Jo-1 patients with ILD, compared with those without, more frequently exhibited mechanic's hands and lower creatine kinase levels.
CONCLUSION: Our findings confirm that ILD is a frequent complication in anti-Jo-1 patients, resulting in high morbidity. We suggest that patients with predictive factors of ILD deterioration may require more aggressive therapy. Finally, anti-Jo-1 patients with ILD, compared with those without, may exhibit a particular clinical phenotype.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23203765     DOI: 10.1002/acr.21895

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  36 in total

1.  Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies.

Authors:  Masaomi Tomonaga; Noriho Sakamoto; Yuji Ishimatsu; Tomoyuki Kakugawa; Tatsuhiko Harada; Shota Nakashima; Atsuko Hara; Shintaro Hara; Yoshihiro Horai; Atsushi Kawakami; Hiroshi Mukae; Shigeru Kohno
Journal:  Lung       Date:  2014-11-14       Impact factor: 2.584

2.  Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Authors:  Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff
Journal:  Chest       Date:  2019-06-22       Impact factor: 9.410

Review 3.  Squamous cell carcinoma of the lung associated with anti-Jo1 antisynthetase syndrome: a case report and review of the literature.

Authors:  G Boleto; J-M Perotin; J-P Eschard; J-H Salmon
Journal:  Rheumatol Int       Date:  2017-04-26       Impact factor: 2.631

4.  Interstitial lung disease in antisynthetase syndrome without clinical myositis.

Authors:  Pranathi Rao Sundaragiri; Saraschandra Vallabhajosyula; Jennifer Papa Kanaan
Journal:  BMJ Case Rep       Date:  2014-04-03

Review 5.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

6.  Antisynthetase syndrome (ASS) presenting as acute respiratory distress syndrome (ARDS) in a patient without myositis features.

Authors:  Venkat Kiran Kanchustambham; Swetha Saladi; Sarah Mahmoudassaf; Setu Patolia
Journal:  BMJ Case Rep       Date:  2016-12-09

7.  Antisynthetase Syndrome: A Rare Cause for ILD.

Authors:  Hj Gayathri Devi; Md Majeed Pasha; Mantha Sathya Padmaja; Sujith Halappa
Journal:  J Clin Diagn Res       Date:  2016-03-01

8.  Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).

Authors:  Jorge Rojas-Serrano; Denisse Herrera-Bringas; Mayra Mejía; Hermes Rivero; Heidegger Mateos-Toledo; José E Figueroa
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

Review 9.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

10.  Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.

Authors:  Alejandro Robles-Perez; Jordi Dorca; Ivan Castellví; Joan Miquel Nolla; Maria Molina-Molina; Javier Narváez
Journal:  Rheumatol Int       Date:  2020-03-10       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.